

for expansion of early T cell precursors. *Genes Dev.* 1999; 13(9):1203-1210.

5. Weng AP, Ferrando AA, Lee W, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. *Science.* 2004;306(5694):269-271.

6. Abrahamsson AE, Geron I, Gotlib J, et al. Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation. *Proc Natl Acad Sci U S A.* 2009; 106(10):3925-3929.

7. Zhao C, Chen A, Jamieson CH, et al. Hedgehog signaling is essential for maintenance of cancer stem cells in myeloid leukaemia. *Nature.* 2009;458(7239):776-779.

8. Jin YH, Kim H, Ki H, et al. Beta-catenin modulates the level and transcriptional activity of Notch1/NICD through its direct interaction. *Biochim Biophys Acta.* 2009;1793(2): 290-299.

9. Shimizu T, Kagawa T, Inoue T, et al. Stabilized beta-catenin functions through TCF/LEF proteins and the Notch/RBP-Jkappa complex to promote proliferation and suppress differentiation of neural precursor cells. *Mol Cell Biol.* 2008;28(24):7427-7441.

10. Ingram WJ, McCue KI, Tran TH, Hallahan AR, Wainwright BJ. Sonic Hedgehog regulates Hes1 through a novel mechanism that is independent of canonical Notch pathway signalling. *Oncogene.* 2008;27(10):1489-1500.

in PMF and PV or ET after evolution to a PMF phenotype. Even more puzzling is *JAK2*<sup>V617F</sup>-negative AL arising in a *JAK2*<sup>V617F</sup>-positive MPD.

To examine these issues, Thoenissen et al used high-density single-nucleotide polymorphism (SNP) arrays to study genomic changes in 148 MPD patients, in chronic phase (CP) and LT. They found a 2- to 3-fold greater incidence of abnormalities with LT. ET patients had fewer abnormalities during CP but matched their MPD counterparts upon transformation. Commonly altered genes in LT included *ETV6*, *TP53*, and *RUNX1*, and *MYC* amplification in *JAK2*<sup>V617F</sup>-negative LT. SNP arrays recognize copy number-neutral loss of heterozygosity (CNN-LOH), and CNN-LOH on either 9p in association with *JAK2*<sup>V617F</sup> homozygosity, or 7q alone correlated with decreased LT survival. CNN-LOH was also found on 16q, 19p, and 21q, implicating additional LT candidate genes and also genetic instability, suggesting that MPD LT is a heterogeneous process. Importantly, 17p deletions involving *TP53* and chromosome 17 CNN-LOH were highly associated with hydroxyurea (HU) therapy and shortened survival. *JAK2*<sup>V617F</sup> did not appear to be associated with time to LT or overall survival. However, because the CP and LT patients were largely unmatched, cause-and-effect associations were not possible.

This is where Beer et al make a very important contribution. They studied 16 MPD patients before and after LT to understand the basis for *JAK2*<sup>V617F</sup>-negative AL arising in a *JAK2*<sup>V617F</sup>-positive MPD. They elegantly demonstrate that this was not caused by mitotic recombination, gene conversion, or gene deletion. They, too, identified some “usual suspects” associated with LT, *RUNX1*, *TP53*, *WT1*, *CBL*, *NRAS*, and *TET2*, and their expression was occasionally present during CP. Importantly, in this matched study, *JAK2*<sup>V617F</sup>-positive LT occurred mainly in PMF or PV and ET patients who had evolved to a PMF phenotype and was associated with *RUNX1* mutations, whereas *JAK2*<sup>V617F</sup>-negative LT occurred in CP PV and ET patients and was associated with *TP53* mutations or deletion. *TP53* mutations and 17p deletions are, of course, a hallmark of HU exposure and, although we have only a numerator, 14 of the 16 patients received HU before LT, including all 9 *JAK2*<sup>V617F</sup>-negative AL patients, 6 of whom received HU alone.

## ● ● ● MYELOID NEOPLASIA

Comment on Thoenissen et al, page 2882, and Beer et al, page 2891


# An inconvenient truth

Jerry L. Spivak JOHNS HOPKINS UNIVERSITY

In this issue of *Blood*, 2 groups—Thoenissen et al and Beer et al—using complementary approaches address the genetic basis for LT in MPDs, PV, ET, and PMF.<sup>1,2</sup>

Leukemic transformation (LT) is the most serious complication of myeloproliferative disorders (MPDs). For polycythemia vera (PV), a minimum spontaneous transformation rate of 1.5% has been established.<sup>3</sup> Prospective studies of adequate duration are lacking for essential thrombocythosis (ET) but LT is un-

likely to be more frequent. For primary myelofibrosis (PMF), however, an LT rate of 15% has been recorded. Treatment-induced acute leukemia (t-AL) occurs at a much higher rate in PV,<sup>3,4</sup> but adequate prospective studies are lacking for ET and PMF. The mechanisms for t-AL are understood, but whether these apply to hydroxyurea as they do for other types of chemotherapy is still controversial. The etiology of spontaneous LT in the MPD is not understood, although it is more common



A model to explain *JAK2*<sup>V617F</sup>-positive and -negative leukemic transformation in the myeloproliferative disorders. Acquisition of *JAK2*<sup>V617F</sup> by a receptive hematopoietic stem cell (HSC) results in a myeloproliferative disorder (MPD). Acquisition of additional mutations due to genetic instability in the expanding clonal cell population favors spontaneous acute leukemia (AL). Exposure to chemotherapeutic agents that damage DNA but prevent its repair (such as HU) favors the emergence of a clonal constituent that is *TP53*-independent, can bypass normal replication checkpoints, and continues to acquire genetic damage until it transforms (t-AL). Alternatively, inhibition of more robust members of the dominant clone by chemotherapy may allow a less robust and more unstable clone to dominate. Finally, selective suppression of the *JAK2*<sup>V617F</sup>-positive clone by targeted therapy or chemotherapy could lead to selection of a member of the “receptive” ancestral clone or transform it, leading to *JAK2*<sup>V617F</sup>-negative AL or t-AL. (Arrow width indicates event probability; arrow length, the time to transformation.)

What should we conclude from these studies? First, CNN-LOH occurring in a CP MPD indicates the presence of genomic instability, probably due to constitutive tyrosine kinase signaling, which promotes apoptosis resistance,<sup>5</sup> augmented homologous recombination, a mutator phenotype,<sup>6</sup> and loss of the tumor suppressor mechanism, heterochromatic gene silencing.<sup>7</sup> These abnormalities may not only explain spontaneous AL in the MPD, particularly in PMF with its large clonal burden, they also are conducive to t-AL. Second, if the data are confirmed, SNP arrays may be a useful guide for MPD prognosis.

Third, with respect to MPD t-AL, HU can now be securely added to the list of agents that are leukemogenic in the MPD because HU is not different from them or even drugs like azathioprine that also impede DNA repair and cause t-AL. This is not to suggest that HU should not be used in the MPD but rather that its use be judicious. In all studies to date, HU has failed to prevent arterial or venous thrombosis or myelofibrosis and has prevented transient ischemic attacks only because it is a nitric oxide donor.<sup>4,8</sup>

Finally, what about *JAK2*<sup>V617F</sup>-negative AL arising in a *JAK2*<sup>V617F</sup>-positive MPD? It is apparent that *JAK2*<sup>V617F</sup> is not the initiating lesion in the MPD, and, because *JAK2*<sup>V617F</sup>-positive cells are more sensitive to HU than *JAK2*<sup>V617F</sup>-negative cells, we may only be transforming or selecting for a more resistant but less robust primitive ancestral clone by targeting the more sensitive one (see figure), suggesting that nonspecific therapy such as pegylated interferon<sup>9</sup> may be more appropriate for MPD than targeted therapies.<sup>10</sup>

*Conflict-of-interest disclosure:* The author declares no competing financial interests. ■

## REFERENCES

1. Thoenissen NH, Krug UO, Lee DH, et al. Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms. *Blood*. 2010; 115(14):2882-2890.
2. Beer PA, Delhommeau F, Lecouedic JP, et al. Two routes to leukemic transformation following a *JAK2* mutation—positive myeloproliferative neoplasm. *Blood*. 2010; 115(14):2891-2900.
3. Berk PD, Goldberg JD, Silverstein MN, et al. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. *N Engl J Med*. 1981;304(8): 441-447.
4. Najean Y, Rain J. Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. *Blood*. 1997;90(9):3370-3377.
5. Zhao R, Follows GA, Beer PA, et al. Inhibition of the

Bcl-xL deamidation pathway in myeloproliferative disorders. *N Engl J Med*. 2008;359(26):2778-2789.

6. Plo I, Nakatake M, Malivert L, et al. *JAK2* stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders. *Blood*. 2008;112(4):1402-1412.

7. Dawson MA, Bannister AJ, Gottgens B, et al. *JAK2* phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. *Nature*. 2009;461(7265):819-822.

8. Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea

compared with anagrelide in high-risk essential thrombocythemia. *N Engl J Med*. 2005;353(1):33-45.

9. Kiladjan JJ, Cassinat B, Chevret S, et al. Pegylated interferon- $\alpha$ -2a induces complete hematological and molecular responses with low toxicity in polycythemia vera. *Blood*. 2008;112(8):3065-3072.

10. Brodsky RA, Jones RJ. Riddle: what do aplastic anemia, acute promyelocytic leukemia, and chronic myeloid leukemia have in common? *Leukemia*. 2004;18(10):1740-1742.

## ● ● ● VASCULAR BIOLOGY

Comment on Wang et al, page 2971

# HDAC5: going with the flow

Paul Huang HARVARD MEDICAL SCHOOL

In this issue of *Blood*, Wang and colleagues uncover a novel mechanism by which fluid shear stress regulates expression of endothelial genes through effects on HDAC5 phosphorylation. The endothelium of blood vessels serves important functions in normal physiology including regulation of vascular tone, endothelial cell survival, smooth muscle cell proliferation, leukocyte recruitment, and thrombosis.<sup>1,2</sup>

**A**bnormalities in endothelial function are critically important to atherosclerosis, as the endothelium is thought to integrate the effects of multiple cardiovascular risk factors on the vessel wall.<sup>3</sup> Endothelial dysfunction can be quantitated in patients by flow-mediated dilation, in which the degree of vasodilation of the brachial artery is measured during reperfusion after a period of vascular occlusion. Endothelial response to flow is very important, but the mechanisms by which fluid shear stress causes changes in endothelial function are not well understood.

Now, Wang et al show that fluid shear stress stimulates phosphorylation of HDAC5, which affects its interactions with MEF2 transcription factor, with subsequent effects on KLF2 activity and endothelial nitric oxide synthase (eNOS) gene expression.<sup>4</sup> This work represents an important advance in the field of vascular biology for several reasons. First, although HDAC5 is known to serve as a negative regulator of MEF2 activity in cardiomyocytes and skeletal muscle cells, this is the first demonstration that HDAC5 activity can be affected by fluid shear stress in endothelial cells. Shear stress induces HDAC5 phosphorylation, which stimulates its nuclear export and interferes with its interactions with MEF2. As a result, the tonic repression of MEF2 activity by HDAC5 is released. Pharmacologic inhibitors establish that flow-induced phosphorylation of HDAC5 is mediated by Ca<sup>2+</sup>

and calmodulin, but does not involve CaM kinase II or protein kinase D (which is involved in VEGF effects on HDAC5).

Second, this study provides further insight into the flow-induced regulation of KLF2 activity. KLF2, a zinc finger transcription factor, regulates leukocyte-endothelial cell interactions, endothelial cell proliferation and migration, and endothelial gene expression including eNOS expression. KLF2 is known to be responsive to flow,<sup>5</sup> and MEF2 is known to be a key transcription factor in its expression. In addition to the MEK/ERK pathway, this paper shows that KLF2 expression can be modulated by effects of flow on HDAC5. Using an unphosphorylatable serine-to-alanine mutant of HDAC5, the authors have elegantly demonstrated that increased activity of both MEF2 and KLF2 promoters in response to flow requires HDAC5 phosphorylation. Interestingly, HDAC5 effects on MEF2 transcription factor activity in response to cytokines involve p65 and NF- $\kappa$ B, while HDAC5 effects in response to flow involve its phosphorylation.<sup>6</sup> Thus, different physiologic signals mediate changes through different but overlapping effector mechanisms.

Third, this study shows that these effects are relevant to processes known to be important to atherogenesis. The functional importance is demonstrated by effects on monocyte